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Abstract 
Background: Prediction models are essential to the development of prediction rules that guide decision-making, 
and comparison of prediction models with and without an additional diagnostic or prognostic risk factor allows 
assessment of the value of the additional factor in risk prediction. However, the many different measures described to 
translate the information provided by a prediction model do not readily assist clinicians’ decision-making.
Results: The clinical utility (CU) curve is proposed as an alternative method of communication of information from a 
prediction model to the clinician. The CU curve is essentially a derivation of the ROC curve that has sensitivity on the 
y-axis and the number needed to capture one case (NNCOC) on the x-axis. It provides information about the relation-
ship between sensitivity and false positive rate over the full range of prediction score thresholds, and it also indicates 
the proportion of the patient population with an absolute risk below the threshold for 100 % sensitivity that can 
therefore be classified as free of disease.
Conclusions: The CU curve is proposed as a means to assist the translation of model information to the clinician, 
in the hope that it will stimulate debate and, through refinement, assist the development of prediction rules with 
optimal clinical utility.
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Background
Prediction models are essential to inform healthcare 
professionals and individuals about the risks of having 
(diagnosis) or developing (prognosis) a particular disease 
or outcome. This information guides clinicians’ decision-
making regarding further management—including addi-
tional testing and initiating or withholding treatment(s) 
and lifestyle changes [1]. Moreover, comparison of pre-
diction models with and without an additional diagnostic 
or prognostic risk factor allows assessment of the value 
of the additional factor in risk prediction. The challenge 
for clinicians is to translate the prediction model to a pre-
diction rule, which requires the definition of a prediction 
score cut-off or threshold [2]. Translation takes a number 
of factors into account, including the sensitivity, specific-
ity, and false positive rate of a particular prediction score 
threshold, and the balance between the potential benefits 
and costs that result from a prediction rule based on the 
threshold (see Additional file 1: Glossary).
Many different measures have been described to trans-
late the information provided by a prediction model to 
decision-making, and for the assessment of the incre-
mental value of additional risk factors. These include the 
use of odds ratios to assess the association of a risk fac-
tor with a clinical outcome, R squared, Brier score and 
integrated discrimination improvement (IDI) indices 
to assess overall performance of the prediction model, 
receiver operating characteristic (ROC) curves and C 
statistics to assess how well the model discriminates 
between patients with and without the disease or out-
come, net reclassification improvement (NRI) to assess 
whether a new model improves patient classification, and 
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net benefit, weighted NRI, decision curve analysis, clini-
cal utility index, and relative utility curves to assess the 
clinical utility of the model [3–6].
These measures for translating information provided 
by prediction models do not readily provide the infor-
mation that clinicians require for decision-making, and 
there is ongoing debate about the appropriateness of 
some of these measures [7, 8]. As discussed by Steyerberg 
et  al. these measures may have limitations with respect 
to specific prediction score thresholds because differ-
ent thresholds can offer different conclusions about the 
relative merits of different prediction models [4], and a 
substantial change in any of these parameters achieved 
by adding a risk factor to a model may not translate to 
clinical usefulness at a given threshold [4, 9]. Although C 
statistics, NRI and IDI may show that a prediction model 
has superior performance, they do not convey informa-
tion about the consequences of the improved perfor-
mance. Net benefit, weighted NRI, clinical utility index, 
relative utility curves, and decision curve analysis may 
appear to offer advantages [4], but a clinical decision 
about weighting is required before the modeler can cal-
culate these parameters. For example, it is the clinician 
who decides how many biopsies of people without can-
cer (and the potential harm from biopsy) justifies one 
correctly diagnosed case of cancer. This clinical decision 
may vary depending on the clinical context, including the 
patient’s age, sex and co-morbidities.
Critical information required by the clinician for 
decision-making includes the sensitivity for detection 
of cases or future cases by a particular prediction score 
threshold, and the corresponding number of false posi-
tives captured by this threshold. Negative predictive 
value is also of importance for the clinician who wants 
to “rule out” a diagnosis or risk. The objective of this 
manuscript is to describe the clinical utility (CU) curve. 
The CU curve is a proposal to improve the translation of 
information provided by prediction models to clinicians. 
This is essentially a derivation of the ROC curve that has 
sensitivity on the y-axis and the number needed to cap-
ture one case (NNCOC) on the x-axis for the full range 
of prediction score thresholds. For example, if a predic-
tion rule is to help decide how many patients to biopsy to 
confirm a diagnosis of cancer, the NNCOC is the number 
of patients that need to be biopsied to diagnose one case 
of cancer. The CU curve therefore provides information 
about the number of false positives for each true positive, 
in relation to sensitivity. The NNCOC (the reciprocal 
of positive predictive value) is analogous to the num-
ber needed to treat, which is the reciprocal of absolute 
risk reduction by a therapeutic intervention. Thus, for 
patients with high blood pressure, the number needed to 
treat refers to the number who need to be treated with 
an antihypertensive agent in order to prevent one cardio-
vascular event [10]. The novelty of the CU curve is that it 
allows the clinician to explore the interplay between sen-
sitivity and false positive rate over a range of prediction 
score thresholds. When taken into account with the cost 
of the test and its potential harm, the CU curve assists 
the clinician in assessing misclassification costs and 
harm-benefit ratio that apply to any particular thresh-
old, and in thereby determining which prediction score 
threshold results in a prediction rule with optimal clinical 
utility.
Methods
Two examples of the CU curve are presented. These are 
for illustrative purposes only, based on publicly avail-
able data [11, 12], and are focused on dichotomous out-
comes. Absolute risk for each patient was calculated 
by performing logistic regression of each multivariable 
model using the PredictABEL package in R. NRI and IDI 
were also computed with the PredictABEL package. C 
statistics were calculated using the pROC package in R. 
The CU curve for a model was constructed by entering 
each patient’s absolute risk determined from the model 
into an Excel spreadsheet together with data about the 
presence or absence of malignancy (example 1) or cor-
onary disease (example 2). The patients were sorted 
according to their absolute risk, then sensitivity, speci-
ficity, NNCOC and other parameters calculated for each 
patient.
Results
Example 1: assessment of the value of a new biomarker
For women with adnexal masses, the clinician wants to 
identify all cases of malignancy. It is also an advantage 
to identify women without malignancy before surgery 
because a simpler surgical procedure may be performed 
in these women. Carter et  al. reported a series of 37 
women with adnexal masses, of which 12 were malignant 
and three had borderline histology (herein combined 
and referred to as malignant) [11]. These authors exam-
ined the predictive ability of quantitative T2 mapping of 
contrast-enhanced imaging of the masses identified by 
magnetic resonance imaging. In the present analysis, 
a prediction model based on age, largest dimension of 
the mass encompassing all regions of interest and num-
ber of solid regions of interest per mass (model 1) was 
compared with a model based on the same 3 parameters 
plus the number of cystic regions of interest per mass 
(model 2). Both models were well calibrated (Hosmer–
Lemeshow test: P  =  0.405 for model 1; P  =  0.413 for 
model 2). The C statistic for model 1 was 0.839 (95 % CI 
0.697–0.947) and for model 2 was 0.877 (0.753–0.968), 
P = 0.003 (bootstrap estimate). Comparing models 1 and 
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2, the NRI (continuous) was 0.74 (0.14–1.34), P = 0.016, 
and the IDI was 0.072 (−0.019 to 0.163), P = 0.120.
The CU curves resemble the respective ROC curves 
when the models are applied to everyone in the dataset, 
except that the x-axis is NNCOC rather than 1-speci-
ficity (Fig. 1). This is to be expected because 1-specific-
ity is the same as the false positive rate (expressed as 
a percentage). The CU curves give the clinician easily 
understood information about the number of surgical 
biopsies required to identify one case of malignancy 
according to the proportion of malignancies identi-
fied (sensitivity) for each model, and the number of 
patients identified without malignancy, whereas the 
ROC curves do not convey this information. The top 
right-hand corner of the CU curve corresponds to the 
NNCOC achieved when all members of the population 
are biopsied, and is always at 100 % sensitivity because 
all malignancies are identified if all patients are biop-
sied. Where the curve reaches 100 % sensitivity before 
all patients are biopsied, the length of the horizontal 
line at 100 % sensitivity indicates the proportion of the 
patient population with a prediction score below the 
threshold for 100  % sensitivity, which can therefore 
be identified as free of malignancy before surgery and 
biopsy.
The CU curve for model 1 shows that it was neces-
sary to biopsy 35 patients with an absolute risk ≥3.7 % to 
identify the 15 with malignancy, producing an NNCOC 
of 2.3 when the CU curve first reached 100 % sensitivity; 
model 1 identified only 2 patients without malignancy. 
By contrast, model 2 identified all 15 patients with malig-
nancy among 30 patients with an absolute risk  ≥6  %; 
thus, the NNCOC was 2 when the CU curve first reached 
100 % sensitivity, and model 2 identified 7 patients with-
out malignancy. Different absolute risks were required 
to identify malignancy with the same sensitivity with 
models 1 and 2. For example, an absolute risk  ≥32  % 
identified 93 % of malignancies using model 1, whereas a 
risk ≥12 % was required to identify 93 % of malignancies 
using model 2 (Fig. 1).
Example 2: comparison of patient subgroups using a 
multivariable prediction model
The prediction of coronary artery disease in men and 
women was compared using a prediction model based 
on a dataset of 303 patients referred to the Cleveland 
Clinic for coronary angiography [12]. None had a his-
tory or electrocardiographic evidence for prior myocar-
dial infarction or known valvular or cardiomyopathic 
disease. There were 206 men and 97 women; 114 men 
and 25 women had one or more coronary arteries 
with  >50  % stenosis. The prediction model was con-
structed using all 303 patients, based on age, sex, char-
acter of chest pain, resting systolic blood pressure on 
admission, serum cholesterol level, fasting blood glu-
cose >120 mg/dl, resting electrocardiograph, maximum 
heart rate achieved during exercise, exercise-induced 
angina, ST segment depression during exercise, slope 
of the ST segment during peak exercise, number of cal-
cified vessels detected by fluoroscopy, and the result of 
an exercise thallium scintigraphy test. The outcome was 
patients with  ≥1 coronary arteries with  >50  % steno-
sis. The model was well calibrated (Hosmer–Lemeshow 
test: P  =  0.367) and the C statistic was 0.873 (0.833–
0.913) (Delong method) [13]. Male sex was a significant 
predictor in the multivariable model with a coefficient 
of 1.98 (SE 0.38).
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Fig. 1 ROC curves (a) and CU curves (b) for the prediction of 
malignancy (combined malignancy and borderline histology) in 
37 women with adnexal masses. Solid line represents model 1 and 
dashed line represents model 2. NNCOC number of surgical biopsies 
needed to capture one case of malignancy. C statistics were 0.839 
(95 % CI 0.697–0.947) for model 1 and 0.877 (0.753–0.968) for model 
2, P = 0.003. Sensitivities of 80, 87, 93 and 100 % were achieved at 
absolute risks of 38, 36, 32 and 3.7 %, respectively, for model 1, and 
64, 30, 12 and 6 %, respectively for model 2. Model 1 identified all 15 
malignancies in 35 patients, with an NNCOC of 2.3, whereas model 2 
identified all 15 malignancies in 30 patients, with an NNCOC of 2
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The ROC curves were similar for men and women, 
with C statistics of 0.846 (0.792–0.900) for men and 0.892 
(0.812–0.973) for women, P  =  0.348 (Delong method) 
[13] (Fig.  2). However, despite the similarity in ROC 
curves, the CU curves show the prediction model per-
formed differently in men and women. The model iden-
tified all 114 men with ≥1 coronary arteries with >50 % 
stenosis in 199 men who underwent coronary angiog-
raphy, with an NNCOC of 1.7 whereas, when applied 
to women, the model identified all 25 women with  ≥1 
coronary arteries with >50 % stenosis in 80 women who 
underwent coronary angiography, with an NNCOC of 
3.2. Different absolute risks were required to identify 
men and women with ≥1 coronary arteries with  >50  % 
stenosis with the same sensitivity. For example, an abso-
lute risk ≥32 % identified 90 % of men, whereas an abso-
lute risk ≥26 % identified 90 % of women with coronary 
artery disease (Fig.  2). Despite the higher NNCOC for 
women, it is evident that the model was better able to 
exclude coronary artery disease in women than in men. 
An absolute risk threshold of 6 % identified only 7 of 92 
men without coronary artery disease, whereas a thresh-
old of 3  % identified 17 of 72 women without coro-
nary artery disease, who may have avoided coronary 
angiography.
Discussion
These two examples indicate how the CU curve may 
improve the translation of information provided by pre-
diction models to clinicians to assist the development of 
prediction rules by directly comparing two models with 
and without an additional risk factor, and by directly 
comparing the performance of a risk model in different 
patient subgroups. The CU curve is based on the same 
information used to calculate the ROC curve, but it pro-
vides a more complete description of this information 
than the ROC curve. The CU curve provides information 
about the relationship between sensitivity and false posi-
tive rate over a range of prediction score thresholds, and 
also indicates the proportion of the patient population 
with an absolute risk below the threshold for 100 % sen-
sitivity that can therefore be identified as free of disease. 
The CU curve assists clinicians in assessing the tradeoff 
between sensitivity and false positive rate, and in apply-
ing their own weighting when they interpret the data.
Going from a prediction model to a prediction rule 
requires the definition of a prediction score threshold 
[2]. Current strategies for comparing prediction mod-
els are not intuitively easy for the clinician to use when 
deciding whether one model is superior to another or 
when choosing a prediction score threshold to use in a 
prediction rule. Steyerberg et  al. recommends that the 
decision-analytic measure net benefit or weighted NRI 
is preferable for the identification of the most informa-
tive prediction model and the prediction score threshold 
that provides greatest clinical utility [4]. Net benefit is a 
measure that explicitly incorporates the relative weight 
for over-diagnosis vs. appropriate diagnosis [14, 15]. 
However, the clinician, not the modeler, decides weight-
ing, and net benefit, weighted NRI, clinical utility index, 
relative utility curves, and decision curve analysis require 
that the clinician has already made a decision about 
weighting before they can be calculated. Another limita-
tion of net benefit, weighted NRI, decision curve analysis, 
clinical utility index and relative utility curves is that they 
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Fig. 2 ROC curves (a) and CU curves (b) for the prediction of patients 
with ≥1 coronary arteries with >50 % stenosis. Solid line represents 
men (n = 206) and dashed line represents women (n = 97). NNCOC, 
number needed to capture one patient with ≥1 coronary arteries 
with >50 % stenosis. C statistics were 0.846 (95 % CI 0.792–0.900) 
for men and 0.892 (0.812–0.973) for women, P = 0.348. The model 
achieved sensitivities of 80, 85, 90, 95 and 100 % at absolute risks of 
46, 38, 32, 15 and 6 %, respectively, for men, and 36, 31, 22, 9 and 3 %, 
respectively, for women. The model identified all 114 men with ≥1 
coronary arteries with >50 % stenosis in 199 men who underwent 
coronary angiography, with an NNCOC of 1.7, whereas when applied 
to women, the model identified all 25 women with ≥1 coronary 
arteries with >50 % stenosis in 80 women who underwent coronary 
angiography, with an NNCOC of 3.2
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do not report sensitivity, which is an important consid-
eration for the clinician who wants a prediction rule that 
benefits the greatest number of individuals.
When managing an individual patient, most physi-
cians implicitly consider the tradeoffs that influence the 
decision whether to administer or withhold therapy, or 
order another test. The CU curve is different from alter-
native methods of assessment of diagnostic or prognostic 
markers in that it helps the clinician assess the interplay 
between sensitivity, false positive rate and prediction 
score threshold without the need for additional calcu-
lations. It also allows assessment of improvement in 
classification because higher sensitivity will reduce false-
negatives, and lower NNCOC will reduce false positives. 
By providing a more intuitive comparison of prediction 
models the CU curve assists the clinician in weighing the 
potential costs, including harm, and benefits of an addi-
tional diagnostic or prognostic marker. If a new marker 
reduces the false positive rate for the same prediction 
score threshold, then the clinician may choose to lower 
the threshold to capture of a greater proportion of cases 
or future cases while maintaining the false-positive rate.
The prediction score threshold for a prediction rule 
should take account of the clinical context and the con-
sequences of a clinical decision based on the prediction 
rule [16]. If cost is a critical factor, then a clinician work-
ing with fewer cost constraints may choose a different 
prediction score threshold than a clinician working with 
more cost constraints. If potential harm, such as from 
diagnostic investigation, is a critical factor, then a clini-
cian with access to skills and technology may choose a 
different prediction score threshold than a clinician with-
out access to these resources. The CU curve allows the 
clinician to choose a prediction score threshold appropri-
ate to their circumstance-specific weighting for detection 
of disease vs. investigating patients without disease.
Multivariable prediction models such as the Framing-
ham and Pooled Cohort Equations for cardiovascular risk 
prediction are applied to populations comprising men and 
women of different ages [17, 18]. However, an important 
concern for the clinician is whether these models per-
form similarly for different patient subgroups. The ROC 
curve may indicate a test with high discrimination, but it 
does not indicate how well the test will perform in differ-
ent populations with different disease prevalence [19]. By 
contrast, the CU curve illustrates how the test performs 
in different populations such as men compared with 
women. By allowing the direct comparison of CU curves 
for patient subgroups, the CU curve assists the clinician 
in determining the optimal prediction score threshold for 
each subgroup. The CU curves for men and women of the 
coronary artery disease cohort in example 2 showed that 
the prediction model performed differently for men and 
women, despite the prediction model algorithm including 
sex as a predictor. The multivariable prediction model of 
the Pooled Cohort Equation similarly failed to adequately 
account for differences between subgroups, as shown by 
the differences between men and women and between 
different age groups in the prediction of cardiovascular 
risk [20]. The clinician is more likely to ask the modeler 
to create separate subgroup-specific prediction models 
if they are aware of the different performance of a risk 
model for different patient subgroups.
Limitations
Like all measures for the translation of information from 
prediction models to prediction rules, the CU curve has 
limitations. It fails to give direct information about the 
negative predictive value for a model. However, a key 
determinant of the negative predictive value is the false-
positive rate, and it is apparent that the negative pre-
dictive value can be maximized by keeping sensitivity 
as high as possible (and false negatives as low as possi-
ble). The figure depicting the CU curve will need to be 
adapted to the model. In the examples shown in Figs. 1 
and 2 it was possible to show NNCOC in absolute units. 
However, for a model with a small positive predictive 
value, the NNCOC may be correspondingly large, and it 
may be necessary to truncate the x-axis or to log trans-
form NNCOC so that the CU curve can most effectively 
translate information about the model to the clinician. 
It is also evident from examples 1 and 2 that CU curves 
can be seen to zigzag, in contrast to ROC curves, because 
the NNCOC is not necessarily a monotonic function of 
absolute risk or sensitivity. The NNCOC, the reciprocal 
of positive predictive value, is calculated from the ratio 
of (true positive plus false positive cases)/true positive 
cases. There is therefore a stepwise incremental change 
in NNCOC determined by the changes in the numbers of 
cases in the numerator and denominator of this relation-
ship, which may cause the CU curve to zigzag. However, 
this imperfection of the CU curve does not detract from 
its ability to translate model information to the clinician. 
Other limitations relate to over-fitting of the CU curve, 
sampling variability and the confidence intervals for the 
NNCOC. Although a bootstrap resampling procedure 
may help to estimate confidence intervals, it would be 
more appropriate to validate the CU curve in separate 
patient populations.
Conclusions
In conclusion, the CU curve is proposed as a means to 
assist the translation of model information to the cli-
nician, in the hope that it will stimulate debate and, 
through refinement, assist the development of prediction 
rules with optimal clinical utility.
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